First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Jeffrey S. Miller, Sarah Cooley et al.|Blood|2018Cited by 406
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow TransplantationCelso Arrais‐Rodrigues, Vanderson Rocha, Christopher Dalley et al.|Journal of Clinical Oncology|2008Cited by 202
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCTAndrew C. Dietz, Blanche P. Alter, Sharon A. Savage et al.|Biology of Blood and Marrow Transplantation|2017Cited by 61
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancerMelissa Khaw, Jeffrey S. Miller, Nicholas A. Zorko et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
Abstract 1241: Enhancing NK cell therapy for head and neck cancer within the solid tumor microenvironment using a B7H3-targeting tri-specific killer engager (TriKE)Melissa Khaw, Jeffrey S. Miller, Carly Selleck et al.|Cancer Research|2024Cited by 0